Rory McIlroy, Daniel Ricciardo, Connor McDavid, Klay Thompson, Jayson Tatum and More Join Naomi Osaka, Erling Haaland and Virat Kohli as Hyperice Athlete-Investors to Fuel Global Growth
Hyperice, a global high-performance wellness brand specializing in percussion, dynamic air compression, vibration, thermal technology, mind technology, and contrast therapy, today announced new investments from superstars across the sports world including professional golfer Rory McIlroy, Formula One (F1) driver Daniel Ricciardo, NHL player Connor McDavid, NBA player Klay Thompson and NBA player Jayson Tatum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005407/en/
Rory McIlroy Joins Join Naomi Osaka, Erling Haaland and Virat Kohli as Hyperice Athlete-Investor to Fuel Global Growth (Photo: Business Wire)
The new investors join an elite list of global athlete-investors such as 4-time tennis Grand Slam champion Naomi Osaka, football superstar Erling Haaland and Indian cricketer Virat Kohli as strategic investors, and quickly follows the company’s entry to mental wellness and evolution into a holistic high-performance wellness brand.
“I am a golfer first and foremost but I am also focused on the long game, which is why I chose to invest in Hyperice,” said professional golfer Rory McIlroy. “Hyperice is an important part of how I practice, play and recover. The company is doing incredible things to redefine and push holistic wellness, so it is an exciting and logical partnership for me and investment partners in Symphony Ventures.”
Other new athlete-investors include 2x NBA All-Star Jayson Tatum, 2x PGA TOUR Champion Tony Finau, 3x NBA Champion Klay Thompson, NBA Champion Khris Middleton, 6x MLB All-Star Nolan Arenado, MLB All-Star Matt Chapman, 4x MLB All-Star Justin Upton, World Series Champion Dexter Fowler, The Masters Champion Sergio Garcia, Professional BMX Athlete Nigel Sylvester, Master Trainer and Performance Specialist Joe Holder, top gaming personality Nicholas Kolcheff, known as NICKMERCS, and more.
These athletes join Hyperice’s current roster of existing high-performing athlete-investors such as Naomi Osaka, Seth Curry, Anthony Davis, Rickie Fowler, DeAndre Jordan, Jarvis Landry, Patrick Mahomes, Christian McCaffrey, Ja Morant, Chris Paul, Ben Simmons, Kelly Slater, Fernando Tatís Jr, J.J. Watt, Russell Westbrook and Trae Young.
“Hyperice’s full suite of products have made a big difference in my recovery and my entire approach to wellness,” said Formula One (F1) driver Daniel Ricciardo. “As Hyperice continues to expand, it felt like the right time to officially put my support into a company that I believe in.”
Now with a global footprint in more than 60 countries, Hyperice is experiencing dramatic global growth driven by an extensive athlete-investors roster, as well as global partnerships in China with the NBA and Leagues of Legends Pro League, the New Zealand national rugby team All Blacks, South Africa national rugby team Springboks, the Mexican Football Federation, and the Tottenham Hotspur Football Club in London.
Reigning National Hockey League (NHL) Most Valuable Player Connor McDavid added: “Hyperice products are a game changer when it comes to supporting both my physical and mental health. Hyperice is not only a brand I personally rely on, but it offers products that benefit all people, no matter what level of athlete they are.”
“This new group of strategic investors will help to fuel Hyperice’s global expansion,” said Jim Huether, Hyperice CEO. “Our international footprint continues to grow with products in more than 60 countries. Partnering with high-performing global athletes like Daniel Ricciardo, Rory McIlroy, Connor McDavid, in addition to the stacked roster we already have, helps continue to separate Hyperice as we continue bringing our innovative suite of products to a broader audience.”
Global Growth and Holistic High-Performance Wellness Brand Evolution
Hyperice recently announced a new stage of global growth as the company evolves into a holistic high-performance wellness brand. The multi-prong transformation, led by Hyperice’s recent acquisition of mental wellness company Core, its third acquisition in the last 18 months, is accompanied by a new brand identity and global brand campaign, and anchored by a suite of new products and industry-first technologies.
Among the new technology advancements include the world's first portable contrast therapy device, Hyperice X, and new generations of Hyperice’s wildly popular Hypervolt and Vyper lines, including the Hypervolt 2, Hypervolt 2 Pro, Vyper 3 and Vyper Go.
- Hyperice X: Last month, Hyperice introduced its latest innovation and the world's first portable contrast therapy device. Hyperice X creates a localized cycle of alternating heat and cold to the knee area for recovery and rehabilitation. Hyperice X will be available globally beginning in 2022.
- Hypervolt 2: The Hypervolt 2 offers noticeable updates from the original, including an improved ergonomic design and reduced weight. Three speeds of powerful percussion help give muscles the relief they’ve been asking for, every day.
- Hypervolt 2 Pro : With the Hypervolt 2 Pro, users will get the same powerful percussion massage therapy that the world’s best athletes have, right in the palm of their hand. Five speeds, set by a new adjustable dial, provide relief to stiff muscles, so users can train and recover like a pro.
- Vyper 3 : All systems activated. The Vyper 3 vibrating roller’s updated design and three speeds help to prime and warm-up the body with a powerful vibrating massage.
- Vyper Go : The next iteration of Hyperice’s “Go” line. Following the release of the Hypervolt Go in 2020, the Vyper Go is a portable, vibrating roller that helps activate muscles, so users can feel their best before activity at home or on the go.
The Vyper 3 is now available in Europe and the United States, and the Hypervolt 2, Hypervolt 2 Pro and Vyper Go are now available in Australia, Canada, China, Europe, New Zealand and the United States with other markets to follow.
Hyperice’s new modern approach and reimagined product innovation allows Hyperice to reimagine how it serves a broader audience of athletes and helps people everywhere do the things they love, and do it more.
For more information, visit hyperice.com. To purchase, please visit country-specific sites: Australia, Canada, China, France, Germany, Italy, New Zealand, Portugal, Spain, UK and the United States.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies in 2021, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005407/en/
Contact information
Jack Taylor PR
Nadine Hachicho
hyperice@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients29.11.2021 17:00:00 EET | Press release
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/ “With AWS as our pre
Celltrion accelerates development of nebulised cocktail therapy (CT-P63 in combination with CT-P59) using its antibody platform to tackle new COVID-19 variants29.11.2021 16:08:00 EET | Press release
Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to respond to emerging mutants from SARS-CoV-2. Targeting newly emerging mutations of SARS-CoV-2 and using its already constructed antibody platform, Celltrion has developed a neutralising antibody cocktail consisting of CT-P63 together with its monoclonal antibody treatment Regkirona (regdanvimab, CT-P59), which was recently approved by the European Commission (EC) for the treatment of COVID-19. Celltrion enrolled 24 healthy volunteers in its global phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of CT-P63 and the company anticipates results by the end of the year. CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. Celltrion plans to evaluate neutralisation of new emerging variants tailored to specific regions and assess poten
FourKites Appoints Industry Veteran to Accelerate Supply Chain Visibility Among European Carriers and Logistics Providers29.11.2021 13:12:00 EET | Press release
Oleksii Kosenko joins FourKites®, the world’s leading real-time supply chain visibility platform, as Director Carrier Network Operations, EMEA, to accelerate the company’s rapidly growing carrier base in Europe. Prior to joining FourKites, Kosenko led the carrier sales teams at Uber Freight and sennder Technologies GmbH, and held a senior sales role at C.H. Robinson. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005303/en/ Oleksii Kosenko joins FourKites as Director Carrier Network Operations, EMEA (Photo: Business Wire) "As today’s supply chain challenges put increasing pressure on carriers across the world, my priority is to ensure that European carriers of all sizes can leverage FourKites to offer better customer service, improve cash flow and cut costs," says Kosenko. "Being able to provide a secure platform for sharing data is what will propel the entire supply chain visibility market into the future, and carrier
Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients29.11.2021 13:00:00 EET | Press release
Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction have not been disclosed. ALASTIN’s premium skincare portfolio is fully incremental to and synergistic with Galderma’s integrated dermatology platform. Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically-proven products for daily skincare regimens and peri-procedural use. ALASTIN’s product offerings are backed by its patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Since inception, ALASTIN has delivered rapid and consistent sales growth, achieving a CAGR
Celonis Accelerates its Process Mining and Execution Management Leadership in India29.11.2021 11:53:00 EET | Press release
Celonis, the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud. As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India. The opportunity for process mining and execution management in India is immense. To provide context, Eve
REPLY: “Cloud in Financial Services” Report Shows Cloud Services Transforming How Value Is Created in the Financial Services Sector29.11.2021 11:30:00 EET | Press release
“Cloud in Financial Services”, a joint report by Reply and Imperial College Business School, provides a one of a kind, in-depth look at how the cloud is set to transform financial services. “Cloud services are here to stay within financial services and the pandemic has only accelerated the move” – commented Nelson Phillips, Professor of Technology Management at the University of California (formerly Professor of Innovation and Strategy and Associate Dean of External Relations at Imperial College Business School) – “But financial institutions need to be strategic in the adoption and there are important questions that need to be addressed as firms progressively move more activity to the cloud. There are significant strategic and organisational challenges that need to be dealt with to ensure cloud adoption is successful and that firms derive maximum value from the move.” Naturally, “Cloud in Financial Services” takes these strategic and organizational challenges head on, addressing the ma
Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India29.11.2021 10:00:00 EET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection (ARI). Rad-G is a rugged, portable, handheld Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximeter and noninvasive respiration rate monitor from the pleth (RRp®). The researchers found that Rad-G was “highly acceptable among health workers” and aided the “timely classification and treatment” of pneumonia—helping them achieve correct case management in more than 91% of cases of ARI and reduce the unnecessary use of antibiotics.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211128005235/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom